topotecan has been researched along with irinotecan in 222 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 71 (31.98) | 18.2507 |
2000's | 84 (37.84) | 29.6817 |
2010's | 57 (25.68) | 24.3611 |
2020's | 10 (4.50) | 2.80 |
Authors | Studies |
---|---|
Boehm, JC; Caranfa, MJ; Faucette, LF; Gallagher, G; Hecht, SM; Holden, KG; Jakas, DR; Johnson, RK; Kingsbury, WD; McCabe, FL | 1 |
Beijnen, JH; de Jong, LA; Hausheer, FH; Maliepaard, M; Pluim, D; Schellens, JH; Tohgo, A; van Gastelen, MA; van Waardenburg, RC | 1 |
LaVoie, EJ; Li, TK; Liu, A; Liu, LF; Ruchelman, AL; Singh, SK | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Friedrich, TD; Guzzo, PR; Jason Herr, R; Nacro, K; Peace, D; Zha, CC | 1 |
Che, X; Ji, H; Miao, Z; Shao, L; Sheng, C; Yao, J; You, L; Zhang, J; Zhang, M; Zhang, W | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Feng, W; LaVoie, EJ; Liu, AA; Liu, LF; Satyanarayana, M; Tsai, YC | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chen, YL; Cheng, CM; Chung, KY; Tseng, CH; Tzeng, CC; Wang, CH | 1 |
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
Che, X; Cheng, P; Dong, G; Feng, H; Guo, W; Liu, W; Luo, C; Miao, Z; Sheng, C; Wang, J; Wang, W; Xu, Y; Yao, J; You, L; Zhang, J; Zhang, W; Zhou, L; Zhu, L | 1 |
Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
Ahluwalia, D; Bhupathi, D; Cai, X; Duan, JX; Hart, CP; Huang, H; Jiao, H; Jung, B; Jung, D; Liu, Q; Matteucci, J; Matteucci, M; Meng, F; Sun, JD | 1 |
Chen, YL; Cheng, CM; Chung, KY; Hsu, CY; Huang, KS; Kao, CL; Tseng, CH; Tzeng, CC | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Dong, G; Guo, Z; Miao, Z; Sheng, C; Wang, S; Yao, J; Zhang, W; Zhang, Y | 1 |
Alloatti, D; Badaloni, E; Cabri, W; Castorina, M; Giannini, G; Pisano, C; Vesci, L | 1 |
Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA | 1 |
Chen, S; Dong, G; Fang, K; Li, J; Liu, N; Miao, Z; Sheng, C; Wang, S; Yao, J; Zhang, W | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Fu, ZD; Huang, JT; Ji, TF; Li, DZ; Li, XY; Lin, JP; Liu, HY; Pan, XD; Song, HX; Wang, CY; Zhang, QZ; Zhang, YL | 1 |
Benetti, E; Centamore, A; Collina, S; Della Volpe, S; Martino, E; Sakaj, M; Sala, A; Terribile, E | 1 |
Chen, HL; Cheng, PL; Goto, M; Hsieh, KY; Lee, KH; Liu, YQ; Morris-Natschke, SL; Yang, GZ; Yang, QR; Zhang, N; Zhang, XS; Zhu, GX | 1 |
Goto, M; Hsieh, KY; Lee, KH; Liu, YQ; Morris-Natschke, SL; Song, ZL; Yang, CJ; Zhang, JX; Zhao, YL | 1 |
Goto, M; Hsu, PL; Lee, KH; Liu, YQ; Morris-Natschke, SL; Shang, XF; Song, ZL; Wang, MJ; Yang, CJ; Yang, QR; Zhang, XS | 1 |
Chen, Y; Gao, JM; Lee, KH; Li, B; Li, H; Liu, YQ; Morris-Natschke, SL; Song, ZL; Wang, MJ; Xu, C; Yang, CJ; Zhang, ZJ; Zhao, XB | 1 |
Dai, X; Jiang, T; Li, J; Qi, X; Wu, G; Yin, R; Yu, R; Zhang, G | 1 |
Ariyoshi, Y; Sugiura, T | 1 |
Burris, HA; Kuhn, JG; Rothenberg, ML; Von Hoff, DD | 1 |
Slichenmyer, WJ; Von Hoff, DD | 1 |
Bonneterre, J | 1 |
Donehower, RC; Grochow, LB; Kaufmann, SH; Rowinsky, EK; Slichenmyer, WJ | 1 |
Ettinger, DS | 1 |
Burke, TG; Malak, H; Mi, Z | 1 |
Cheshire, PJ; Danks, MK; Friedman, HS; Hallman, JD; Houghton, JA; Houghton, PJ; Lutz, L | 1 |
Cheson, B; Christian, M; Feigal, EG; Friedman, MA; Grever, M | 1 |
Sinha, BK | 1 |
Burris, HA; Eckardt, JR; Fields, S; O'Rourke, T; Rodriguez, GI; Rothenberg, ML; Weiss, GR | 1 |
Capranico, G; D'Incalci, M; Garattini, S; Giaccone, G; Zunino, F | 1 |
Grant, SC; Kris, MG; Miller, VA; Pisters, KM; Rigas, JR | 1 |
Schellens, JH; Verweij, J | 1 |
Burris, HA; Fields, SM | 1 |
Burris, HA; Chen, SF; Eckardt, J; Fields, SM; Kuhn, JG; Rothenberg, M; Von Hoff, DD | 1 |
Funk, LR; Hofmann, GA; Johnson, RK; Mattern, MR; McCabe, FL; Polsky, RM | 1 |
Green, MR | 1 |
Cassidy, J; Graham, MA; Jodrell, D; Kaye, SB; Workman, P | 1 |
Burke, TG; Mi, Z | 1 |
Creemers, GJ; Lund, B; Verweij, J | 1 |
Donehower, RC; Kaufmann, SH; Rowinsky, EK; Slichenmyer, WJ | 1 |
Beran, M; Cazenave, L; Ellis, A; Kantarjian, HM; Keating, MJ; Koller, C; O'Brien, S; Plunkett, W; Rios, MB; Zwelling, L | 1 |
Furue, H | 1 |
Bissery, MC; Cheshire, PJ; Hallman, JC; Houghton, JA; Houghton, PJ; Mathieu-Boué, A | 1 |
Donehower, RC; Slichenmyer, WJ | 1 |
Dancey, J; Eisenhauer, EA | 1 |
Drengler, R; Eckardt, J; Eckhardt, G; Villalona-Calero, M; Von Hoff, D | 1 |
Mani, S; Ratain, MJ | 1 |
Danks, MK; Houghton, JA; Houghton, PJ; Luo, X; Stewart, CF; Thompson, J; Zamboni, WC | 1 |
Friedman, HS; Houghton, PJ | 1 |
Willson, JK | 1 |
Gutzler, F | 1 |
Burke, TG; Warner, DL | 1 |
Ishii, M; Joto, N; Kuga, H; Minami, M; Mitsui, I; Tohgo, A | 1 |
de Jonge, MJ; Gerrits, CJ; Schellens, JH; Stoter, G; Verweij, J | 1 |
Kono, A; Kumazawa, E; Shimazoe, T; Takiguchi, S; Tohgo, A | 1 |
Furuse, K | 1 |
Sugiyama, T; Ushijima, K; Yakushiji, M | 1 |
Rothenberg, ML | 1 |
Negoro, S | 1 |
Kaye, SB; Vasey, PA | 1 |
Ghaemmaghami, M; Jett, JR | 1 |
Astoul, C; Ollitrault, N; Salvat, D | 1 |
Boersma, AW; Ma, J; Maliepaard, M; Nooter, K; Schellens, JH; Stoter, G; Verweij, J | 1 |
Ardouin, P; Bénard, J; Boland, I; Cappelli, C; Gouyette, A; Hartmann, O; Morizet, J; Pondarré, C; Terrier-Lacombe, MJ; Vassal, G; Vénuat, AM | 1 |
Arbuck, SG; Kieffer, LV; Takimoto, CH | 1 |
Bunn, PA; Kelly, K | 1 |
Boland, I; Cappelli, C; Gouyette, A; Imadalou, K; Lucchi, E; Morizet, J; Pein, F; Pondarré, C; Santos, A; Thomas, C; Vassal, G | 1 |
Kolker, HJ; Loos, WJ; Ma, J; Maliepaard, M; Nooter, K; Schellens, JH; Stoter, G; Verweij, J | 1 |
McCann, J | 1 |
Punt, CJ | 1 |
Brown, R; McDonald, AC | 1 |
Beijnen, JH; Herben, VM; Schellens, JH; Ten Bokkel Huinink, WW | 1 |
de Jonge, MJ; Sparreboom, A; Verweij, J | 1 |
Arbuck, SG; Takimoto, CH | 1 |
Muggia, FM; O'Leary, J | 1 |
Chuang, N; Cohen, HW; O'Leary, JJ; Potmesil, M; Ren, CJ; Shapiro, RL | 1 |
Berger, NA; Whitacre, CM; Willson, JK; Zborowska, E | 1 |
de Jong, LA; Floot, BG; Maliepaard, M; Pluim, D; Ruevekamp-Helmers, MC; Schellens, JH; van Gastelen, MA; van Waardenburg, RC | 1 |
Ardizzoni, A; de Cupis, A; Favoni, RE; Grossi, F; Loprevite, M; Merlo, F; Pirani, P | 1 |
Clark, GM; De Jager, RL; Izbicka, E; Lawrence, RA; Rowinsky, EK; Tohgo, A; Von Hoff, DD; Weitman, SD | 1 |
Bom, D; Burke, TG; Curran, DP; Erff, M; Pollack, IF; Strode, JT | 1 |
Chen, AY; Choy, H; Rothenberg, ML | 1 |
Bates, SE; Brangi, M; Ciotti, M; Fojo, T; Kohlhagen, G; Litman, T; Nishiyama, K; Pommier, Y; Robey, R; Takimoto, C | 1 |
Blanke, CD; Rothenberg, ML | 1 |
Groshen, S; Keshelava, N; Reynolds, CP | 1 |
Boisdron-Celle, M; Boulanger, N; Gamelin, E | 1 |
Kelly, K | 2 |
Bigg, DC; Bronckart, Y; Chaboteaux, C; da Costa, PM; Decaestecker, C; Gordover, L; Harper, L; Kiss, R; Lavergne, O; Lesueur-Ginot, L; Malonne, H; Philippart, P | 1 |
Arbuck, SG; Kieffer, LV; Kieffer, ME; Takimoto, CH; Wright, J | 1 |
Allegra, CJ; Grem, JL; Paull, K; Pommier, Y; Voeller, DM | 1 |
Rivory, LP; Robert, J | 1 |
de Bruijn, P; Loos, WJ; Sparreboom, A; Verweij, J | 1 |
Sandler, A | 1 |
Furman, W; Houghton, PJ; Radomski, K; Rodriguez-Galindo, C; Santana, VM; Stewart, CF | 1 |
Dhar, S; Graf, W; Jonsson, B; Jonsson, E; Larsson, R; Nygren, P | 1 |
Beijnen, JH; Jonker, JW; Maliepaard, M; Scheffer, GL; Schellens, JH; Scheper, RJ; Schinkel, AH; Smit, JW | 1 |
Bible, KC; Boerner, SA; Erlichman, C; Hallgren, CG; James, CD; Kaufmann, SH; Maliepaard, M; Ross, DD; Scheffer, GL; Spieker, R; Wang, XY | 1 |
Smart, T | 1 |
Lokich, J | 1 |
Burkey, B; Cmelak, A; Douglas, S; Murphy, BA; Netterville, J; Shyr, Y; Smith, W | 1 |
Bates, SE; Dean, M; Honjo, Y; Hrycyna, CA; Litman, T; Medina-Pérez, WY; Robey, RW; van de Laar, A; Yan, QW | 1 |
Boccieri, MG; Bruschi, G; Lo Re, G; Saracchini, S; Toffoli, G; Tumolo, S | 1 |
Berg, SL; Blaney, SM; Bomgaars, L | 1 |
Gatto, B; Moro, S; Palumbo, M; Sissi, C; Zagotto, G | 1 |
Cunha, KS; Graf, U; Reguly, ML; Rodrigues de Andrade, HH | 1 |
Kato, Y; Saijo, N | 1 |
Imai, Y; Ishikawa, E; Sugimoto, Y; Tsukahara, S; Tsuruo, T | 1 |
Houghton, PJ; Santana, VM | 1 |
Boven, E; Hausheer, FH; Pinedo, HM; Schlüper, HM; Van Hattum, AH | 1 |
Loos, WJ; Mathijssen, RH; Sparreboom, A; Verweij, J | 1 |
Adams, R; Albritton, K; Coffin, C; Goldsby, R; Pulsipher, M; Wagner, L | 1 |
Imai, Y; Ishikawa, E; Kage, K; Miki, Y; Nakane, M; Sugimoto, Y; Tsukahara, S; Tsuruo, T | 1 |
Sandler, AB | 1 |
Bailly, C; Lansiaux, A | 1 |
Ardizzoni, A; de Cupis, A; Favoni, RE; Loprevite, M; Pirani, P; Semino, C | 1 |
Doi, S; Kamihira, S; Kawabata, S; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Sugahara, K; Tsurutani, J; Yamada, Y | 1 |
Bukowski, R; Canetta, R; Ganapathi, R; Grabowski, D; Lee, F; Markman, M; Mekhail, T; Peck, R; Takigawa, N; Uyar, D | 1 |
Evans, SS; Harper, SM; Nagourney, RA; Radecki, S; Sommers, BL | 1 |
Soepenberg, O; Sparreboom, A; Verweij, J | 1 |
Doi, S; Ikegami, Y; Kitazaki, T; Kohno, S; Mizuta, Y; Murase, K; Nakamura, Y; Nakatomi, K; Oka, M; Ross, DD; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M | 1 |
Cheung, NK; Kramer, K; Kushner, BH; Modak, S | 2 |
Bates, SE; Blayney, M; Mistry, P; Morisaki, K; Polgar, O; Robey, RW; Steadman, K | 1 |
Buchdunger, E; Germain, GS; Harwood, FC; Houghton, PJ; Schuetz, JD; Stewart, CF; Traxler, P | 1 |
Hayakawa, Y | 1 |
Holcombe, RF; Kong, KM; Wimmer, D | 1 |
Cho, LC; Choy, H | 1 |
Beijnen, JH; Borst, P; Breedveld, P; Pluim, D; Schellens, JH; Schinkel, AH; Sönmezer, O; Tibben, MM; van Tellingen, O; Zelcer, N | 1 |
Yang, S; Zhang, WN | 1 |
Asada, S; Imai, Y; Ishikawa, E; Sugimoto, Y; Tsukahara, S; Yanase, K | 1 |
Ganapathi, R; Malathi, K; Paranjape, JM; Silverman, RH | 1 |
Murphy, BA | 1 |
Seiter, K | 1 |
Doi, S; Ikegami, Y; Itoh, A; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M | 1 |
Fujita, F; Fujita, M; Fujiwara, T; Kakushima, M; Kawaguchi, T; Kiuchi, S; Koike, M; Kudoh, S; Okuno, S; Sakamoto, Y; Yano, S; Yano, T | 1 |
Cain, A; Crews, KR; Daw, NC; Furman, W; Houghton, PH; Panetta, JC; Rodriguez-Galindo, C; Santana, VM; Stewart, CF; Tan, M | 1 |
Bourget, P; Gravel, E; Mercier, L; Paci, A | 1 |
Cree, IA; Di Nicolantonio, F; Di Palma, S; Fernando, A; Gabriel, FG; Glaysher, S; Gulliford, T; Higgins, B; Hurren, J; Johnson, P; Knight, LA; Lamont, A; Mercer, SJ; Sharma, S; Somers, SS; Toh, S; Whitehouse, PA; Yiangou, C | 1 |
Barone, G; Carminati, P; D'Incalci, M; Di Francesco, AM; Frapolli, R; Meco, D; Pisano, C; Riccardi, A; Riccardi, AS; Riccardi, R; Rutella, S; Zucchetti, M | 1 |
LaVoie, EJ; Liu, AA; Liu, LF; Ruchelman, AL; Zhou, N; Zhu, S | 1 |
Fukuda, M; Kitazaki, T; Kohno, S; Nagashima, S; Nakamura, Y; Oka, M; Shiozawa, K; Soda, H; Takemura, M; Tsukamoto, K; Yabuuchi, H | 1 |
Belfiore, P; Croce, AC; Dal Bo, L; Farina, C; Misiano, P; Petrangolini, G; Pratesi, G; Supino, R; Tortoreto, M; Zunino, F | 1 |
Pujol, JL | 1 |
Fournel, P | 1 |
Anderson, JR; Breitfeld, PP; Lager, JJ; Lyden, ER; Meyer, WH; Pappo, AS | 1 |
Leu, YL; Prijovich, ZM; Roffler, SR | 1 |
Gupta, AA; Pappo, AS | 1 |
Cai, Y; Chen, Y; Ding, J; Gao, H; Huang, M; Jiang, H; Lin, L; Lu, W; Miao, Z; Shen, H; Zhang, J; Zhang, X; Zhu, H | 1 |
Chang, J; Cheon, SH; Cho, BC; Choi, HJ; Jung, JY; Kim, JH; Kim, SK; Shin, SJ; Sohn, JH | 1 |
Gounder, MK; Kulkarni, D; Nazar, AS; Pungaliya, P; Rubin, EH; Saleem, A; Versace, R | 1 |
Baker, SD; Chatelut, E; Mathijssen, RH; Rowinsky, EK; Sparreboom, A; Verweij, J; Wolff, AC | 1 |
Arimura, K; Armstrong, DL; Bhattacharjee, MB; Boerkoel, CF; Champoux, JJ; Choi, K; Deguchi, K; Hirano, R; Huang, C; Inoue, K; Interthal, H; Izumo, S; Nakamura, T; Northrop, JL; Salih, MA; Takashima, H; Umehara, F | 1 |
An, CH; Cho, EK; Choi, SJ; Jeong, SH; Kim, Y; Kyung, SY; Lee, JH; Lee, JI; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB | 1 |
Duh, MS; Lefebvre, P; Neary, M; Reynolds Weiner, J; Skarin, AT | 1 |
Adams, DJ; Giles, F; Jacobsen, TF; Myhren, F; Rizzieri, DA; Sandvold, ML | 1 |
Feun, L; Savaraj, N | 1 |
Herzog, TJ; Wethington, SL; Wright, JD | 1 |
Agata, N; Bagley, RG; Battle, T; Crawford, J; Ewesuedo, R; Krumbholz, R; Kurtzberg, LS; Lavoie, EJ; Roth, S; Rouleau, C; Schmid, S; Teicher, BA; Wang, F; Yao, M; Yu, XJ | 1 |
Srinivas, NR | 1 |
Al-Rejaie, SS; Al-Shabanah, OA; Al-Yahya, AA; Aleisa, AM; Ashour, AE; Attia, SM; Bakheet, SA | 1 |
Chen, GQ; Cheng, JK; Han, YH; Liao, SH; Wang, LS; Wang, XL; Xia, L; Zheng, Y | 1 |
Jiang, C; Jin, W; Li, M; Lou, L; Tang, W; You, T; Zheng, C | 1 |
Balamuth, N; Brodeur, GM; Evans, AE; Ho, R; Iyer, R; Maris, JM; Minturn, JE; Qi, X; Zhao, H | 1 |
Cruz-Munoz, W; Hashimoto, K; Kerbel, RS; Kumar, R; Man, S; Tang, T; Xu, P | 1 |
Antonijevic, MD; Forster, RE; Heaysman, CL; Lewis, AL; Lloyd, AW; Macfarlane, W; Phillips, GJ; Small, SA; Tang, Y | 1 |
Bodiagin, DA; Pokrovskiĭ, VS; Treshchalin, MI; Treshchalina, EM | 1 |
Bouvet, M; Hoffman, RM; Kawaguchi, T; Li, X; Ma, H; Okuno, S; Yagi, S; Yang, Z | 1 |
Aucélio, RQ; da Cunha, AL; Marques, FF | 1 |
Gmeiner, WH; Pommier, Y; Reinhold, WC | 1 |
Kumabe, T; Niizuma, H; Osawa, S; Saito, R; Sonoda, Y; Tominaga, T; Watanabe, M | 1 |
Azzariti, A; Cantore, M; Cassano, G; Colabufo, NA; Gasparre, G; Iannelli, G; Panaro, MA; Paradiso, A; Porcelli, L; Quatrale, AE; Tommasi, S | 1 |
Lansiaux, A; Pourquier, P | 1 |
Miller, G | 1 |
Bowyer, C; Forster, RE; Lewis, AL; Lloyd, AW; Macfarlane, W; Phillips, GJ; Tang, Y | 1 |
Fukuda, K; Imai, Y; Ueda, Y; Yamagishi, H; Yoshimori, M | 1 |
Borst, P; Greenberger, L; Jonkers, J; Rottenberg, S; Sol, W; van Tellingen, O; Zander, SA; Zhang, Y | 1 |
Hui, C; McVey, M; South, A; Thomas, AM | 1 |
Akamatsu, H; Endo, M; Kenmotsu, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Wakuda, K; Yamamoto, N | 1 |
Lin, B; Shao, L; Song, Z; Zhang, Y | 1 |
Beijnen, JH; Iusuf, D; Lin, F; Marchetti, S; Mazzanti, R; Pluim, D; Schellens, JH; van Tellingen, O | 1 |
Balslev, E; Brünner, N; Kümler, I; Nielsen, DL; Stenvang, J | 1 |
Abu-Rustum, NR; Andikyan, V; Barakat, RR; Chi, DS; Khoury-Collado, F; Konner, JA; O'Cearbhaill, RE; Sandadi, S; Sonoda, Y; Tew, WP | 1 |
Aisner, J; Axelrod, RS; Dahlberg, SE; Gounder, M; Owonikoko, TK; Ramalingam, SS; Rausch, PG; Rubin, EH; Schiller, JH; Wang, XV | 1 |
Bloomfield, A; Dorton, R; Guan, J; Leamon, CP; Nelson, M; Reddy, JA; Vetzel, M | 1 |
Hamilton, G; Klameth, L; Rath, B; Thalhammer, T | 1 |
Banville, M; Collins, C; Cruz-Muñoz, W; Di Desidero, T; Hashimoto, K; Jaramillo, ML; Kerbel, RS; Man, S; O'Connor-McCourt, MD; Xu, P | 1 |
Hamasaki, T; Hisamatsu, T; Kawano, M; Kimura, T; Kishimoto, T; Mabuchi, S; Matsumoto, Y; Sasano, T; Sawada, K; Takahashi, K; Takahashi, R; Takahashi, T | 1 |
Barnes, CS; Charlton, P; Doroshow, JH; Guha, R; Jones, J; Jossé, R; Martin, SE; Morris, J; Ormanoglu, P; Pfister, TD; Pollard, JR; Pommier, Y; Reaper, PM | 1 |
Arakawa, Y | 1 |
Gjerset, RA; Zhao, M | 1 |
Burnouf, PA; Chen, KC; Cheng, TL; Chou, HC; Huang, PT; Leu, YL; Prijovich, ZM; Roffler, SR | 1 |
Goto, K; Hida, T; Imamura, F; Kiura, K; Kozuki, T; Mori, K; Nakagawa, K; Nishio, M; Ohe, Y; Okamoto, H; Satouchi, M; Sawa, T; Seto, T; Shibata, T; Takahashi, T; Takeda, K; Tamura, T; Tanaka, H; Yoshimura, N | 1 |
Anderson, RG; Bischak, MM; Broskin, SA; Campbell, CA; Foltz, LE; Higby, KJ; Koper, JA; Nickle, AC; Resendes, KK | 1 |
Bunn, PA; Chan, DC; Drummond, DC; Fitzgerald, JB; Gaddy, DF; Hendriks, BS; Kalra, AV; Klinz, SG; Lee, H; Leonard, SC; Paz, N | 1 |
Li, Q; Sun, L; Wen, F; Zhang, P; Zheng, H; Zhou, J; Zhou, K | 1 |
Amaria, R; Ashkin, E; Bernatchez, C; Chen, Y; Davis, RE; Devi, S; Forget, MA; Haymaker, C; Heffernan, T; Hu, J; Huang, L; Hwu, P; Kalra, A; Liu, C; Malu, S; Mbofung, RM; McKenzie, JA; Muller, F; Peng, W; Pradeep, S; Roszik, J; Satani, N; Sood, A; Tieu, T; Williams, L; Xu, C; Zhang, M; Zorro Manrique, S | 1 |
Chen, Y; Cheng, JG; Liu, Y; Yu, HJ | 1 |
Brandetti, E; Cifaldi, L; Ognibene, M; Pezzolo, A; Pistoia, V; Veneziani, I | 1 |
Jiang, S; Lan, S; Ma, D; Mao, D; Shi, K; Yang, X | 1 |
Nazha, B; Owonikoko, TK | 1 |
Pommier, Y; Thomas, A | 1 |
Bakhutashvili, I; Banovac, F; Esparza-Trujillo, JA; Henman, A; Karanian, JW; Krishnasamy, VP; Levy, EB; Lewis, AL; Mikhail, AS; Negussie, AH; Pritchard, WF; Tang, Y; Wakim, PG; Willis, SL; Wood, BJ; Woods, DL | 1 |
Blanc, E; Bouleftour, W; Forges, F; Guitton, J; Hugues, M; Macé, A; Macron, C; Menguy, S; Raymond, B; Simoëns, X; Tinquaut, F | 1 |
Elloumi, F; Jo, U; Kim, SH; Murai, Y; Pommier, Y; Rajapakse, VN; Saha, LK; Schultz, CW; Senatorov, IS; Takahashi, N; Thomas, A; Zenke, FT; Zimmermann, A | 1 |
Abdullah, H; Agrawal, S; Deng, M; Meeker, C; Sreekrishnanilayam, K; Vijayvergia, N; Yeung, HM | 1 |
Alonso, C; Martín-Encinas, E; Palacios, F; Selas, A | 1 |
Bonnabry, P; Fleury-Souverain, S; Guillarme, D; Maurin, J; Rudaz, S | 1 |
Jiang, M; Wang, X; Wang, Y; Yao, L; Zhuang, Y | 1 |
Bartlett, MG; King, GM; Mensah, GAK; Roberts, AG; Schaefer, KG | 1 |
69 review(s) available for topotecan and irinotecan
Article | Year |
---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The long story of camptothecin: From traditional medicine to drugs.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptotheca; Camptothecin; DNA Topoisomerases, Type I; Humans; Medicine, Traditional; Neoplasms; Structure-Activity Relationship | 2017 |
[DNA topoisomerase inhibitor].
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Phenazines; Topoisomerase I Inhibitors; Topotecan | 1992 |
Clinical trials with the topoisomerase I inhibitors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Forecasting; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1992 |
New natural products in cancer chemotherapy.
Topics: Adenocarcinoma; Alkaloids; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Chemical Phenomena; Chemistry; Drugs, Investigational; Harringtonines; Homoharringtonine; Humans; Infusions, Intravenous; Irinotecan; Melanoma; Paclitaxel; Phytotherapy; Plant Extracts; Plants, Medicinal; Topotecan | 1990 |
[Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan].
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials, Phase II as Topic; Diarrhea; Drug Administration Schedule; Humans; Irinotecan; Neoplasms; Neutropenia; Topoisomerase I Inhibitors; Topotecan; Vomiting | 1995 |
New drugs for treating small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan | 1995 |
New chemotherapeutic agents in non-small-cell lung cancer.
Topics: Aminopterin; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Design; Humans; Interferons; Irinotecan; Lung Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine | 1993 |
Topoisomerase inhibitors. A review of their therapeutic potential in cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Humans; Irinotecan; Neoplasms; Podophyllotoxin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1995 |
New anticancer agents.
Topics: Adenine; Animals; Antineoplastic Agents; Camptothecin; Deoxycytidine; Gemcitabine; Humans; Imides; Indoles; Irinotecan; Isoquinolines; Naphthalimides; Organophosphonates; Pyridines; Topotecan; Vinblastine; Vinorelbine | 1994 |
DNA topoisomerase inhibitors.
Topics: Animals; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Interactions; Drug Resistance; Etoposide; Humans; Irinotecan; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1994 |
New chemotherapeutic agents for non-small cell lung cancer.
Topics: Aminopterin; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Quinoxalines; Sulfanilamides; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1995 |
Topoisomerase I inhibitors. An overview of the camptothecin analogs.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; DNA Topoisomerases, Type I; Drug Resistance; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan | 1994 |
New directions for chemotherapy in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine | 1993 |
Pharmacokinetics and early clinical studies of selected new drugs.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Aziridines; Camptothecin; Clinical Trials, Phase I as Topic; Humans; Indolequinones; Indoles; Irinotecan; Lactones; Macrolides; Neoplasms; Suramin; Topotecan | 1993 |
Topoisomerase I inhibitors: topotecan and irenotecan.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Resistance; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1994 |
The current status of camptothecin analogues as antitumor agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Combined Modality Therapy; DNA Topoisomerases, Type I; Forecasting; Humans; Irinotecan; Topotecan | 1993 |
[Topoisomerase inhibitors developing in Japan].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzopyrans; Camptothecin; Diketopiperazines; Glycosides; Humans; Irinotecan; Neoplasms; Phenazines; Piperazines; Razoxane; Topotecan | 1993 |
Recent clinical advances with camptothecin analogues.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Neoplasms; Topotecan | 1995 |
Current perspectives on camptothecins in cancer treatment.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1996 |
New anticancer agents in clinical development.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; DNA Topoisomerases, Type I; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Irinotecan; Paclitaxel; Prodrugs; Taxoids; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan | 1995 |
Promising new agents in oncologic treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Mice; Microtubules; Neoplasm Proteins; Neoplasms; Paclitaxel; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan | 1996 |
Topoisomerase-I inhibitors in the management of colon cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan | 1996 |
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1997 |
[Lung cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1997 |
[Promising new drugs for gynecological cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase I as Topic; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Genital Neoplasms, Female; Humans; Irinotecan; Organoplatinum Compounds; Paclitaxel; Taxoids; Topotecan | 1997 |
Topoisomerase I inhibitors: review and update.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan | 1997 |
["State-of-the-art" chemotherapy for small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vincristine | 1997 |
New agents in the treatment of small cell lung cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drugs, Investigational; Gemcitabine; Humans; Immunologic Factors; Irinotecan; Lung Neoplasms; Menogaril; Paclitaxel; Taxoids; Teniposide; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
DNA topoisomerase I inhibitors.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Camptothecin; DNA Damage; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1997 |
New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1998 |
Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology.
Topics: Animals; Camptothecin; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1998 |
New drugs in the treatment of colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Topotecan; Trimetrexate; Uracil | 1998 |
Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan | 1998 |
The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Irinotecan; Paclitaxel; Topoisomerase I Inhibitors; Topotecan | 1998 |
An overview of topoisomerase I-targeting agents.
Topics: Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1998 |
Camptothecins: a review of their development and schedules of administration.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; Drug Administration Schedule; Humans; Irinotecan; Neoplasms; Topotecan | 1998 |
DNA topoisomerase I-targeting drugs as radiation sensitizers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Colonic Neoplasms; Combined Modality Therapy; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Enzyme Inhibitors; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Radiation-Sensitizing Agents; Topotecan | 1999 |
Topoisomerase I inhibitors in the treatment of colorectal cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan | 1999 |
[Pharmacokinetic monitoring].
Topics: Antineoplastic Agents; Body Mass Index; Camptothecin; Colorectal Neoplasms; Drug Interactions; Drug Monitoring; Etoposide; Fluorouracil; Humans; Irinotecan; Liver; Paclitaxel; Topotecan | 2000 |
New chemotherapy agents for small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Topotecan; Vinblastine; Vinorelbine | 2000 |
DNA topoisomerase I poisons.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Camptothecin; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors; Topotecan | 1999 |
[Pharmacology of camptothecin and its derivatives].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA Replication; DNA Topoisomerases, Type I; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Irinotecan; Mutation; Topotecan | 1995 |
Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan | 2000 |
Extensive small-cell lung cancer: a treatment overview.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine | 2000 |
Clinical use of topoisomerase I inhibitors in anticancer treatment.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Mice; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2000 |
Treatment of extensive stage small cell lung cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Genes, Dominant; Growth Substances; Humans; Irinotecan; Lung Neoplasms; Metalloendopeptidases; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasm Staging; Oncogenes; Paclitaxel; Palliative Care; Protease Inhibitors; Randomized Controlled Trials as Topic; Salvage Therapy; Signal Transduction; Taxoids; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Topoisomerase I inhibitors in the treatment of head and neck cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Enzyme Inhibitors; Head and Neck Neoplasms; Humans; Irinotecan; Survival Analysis; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2001 |
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2001 |
The development of camptothecin analogs in childhood cancers.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Humans; Infant; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2001 |
Quantitation of camptothecin and related compounds.
Topics: Camptothecin; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan | 2001 |
[Developed new agents for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2002 |
Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chemical Phenomena; Chemistry, Physical; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2002 |
Chemotherapy for small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Irinotecan; Lung Neoplasms; Palliative Care; Peripheral Blood Stem Cell Transplantation; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Topotecan | 2003 |
Clinical studies of camptothecin and derivatives.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Mutagens; Topotecan | 2003 |
Topoisomerase I inhibitors in the combined-modality therapy of lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Enzyme Inhibitors; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoadjuvant Therapy; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors; Topotecan | 2004 |
[Homocamptothecins--novel promising anticancer drugs as inhibitors of topoisomerase I].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; DNA Damage; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 2004 |
Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck.
Topics: Camptothecin; Carcinoma, Squamous Cell; Clinical Trials as Topic; DNA Topoisomerases, Type I; Head and Neck Neoplasms; Humans; Irinotecan; Neoplasm Recurrence, Local; Topoisomerase I Inhibitors; Topotecan | 2005 |
Toxicity of the topoisomerase I inhibitors.
Topics: Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Irinotecan; Renal Insufficiency; Topoisomerase I Inhibitors; Topotecan | 2005 |
Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Humans; Ifosfamide; Irinotecan; Lymphatic Metastasis; Male; Rhabdomyosarcoma; Survival Analysis; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome | 2006 |
New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children.
Topics: Animals; Camptothecin; Child; Disease Models, Animal; Drug Design; Enzyme Inhibitors; Humans; Irinotecan; Rhabdomyosarcoma; Sarcoma; Survival Rate; Topoisomerase I Inhibitors; Topotecan | 2006 |
Topoisomerase I inhibitors for the treatment of brain tumors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Glioblastoma; Humans; Irinotecan; Neoplasm Recurrence, Local; Survival Analysis; Topoisomerase I Inhibitors; Topotecan | 2008 |
Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.
Topics: Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2008 |
[Molecular determinants of response to topoisomerase I inhibitors].
Topics: Camptothecin; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan | 2011 |
A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; DNA Topoisomerases, Type I; Female; Humans; Irinotecan; Neoplasm Metastasis; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2013 |
Targeting Topoisomerase I in the Era of Precision Medicine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; DNA Topoisomerases, Type I; Humans; Irinotecan; Molecular Targeted Therapy; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Precision Medicine; Topoisomerase I Inhibitors; Topotecan | 2019 |
The design and discovery of topoisomerase I inhibitors as anticancer therapies.
Topics: Antineoplastic Agents; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2022 |
The recent developments of camptothecin and its derivatives as potential anti-tumor agents.
Topics: Antineoplastic Agents; COVID-19; Drug Liberation; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan | 2023 |
10 trial(s) available for topotecan and irinotecan
Article | Year |
---|---|
Camptothecin analogues: studies from the Johns Hopkins Oncology Center.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Kidney; Leukemia; Liver; Metabolic Clearance Rate; Neoplasms; Platelet Count; Topoisomerase I Inhibitors; Topotecan | 1994 |
Preclinical and phase I trials of topoisomerase I inhibitors.
Topics: Antineoplastic Agents; Camptothecin; Cell Line; Female; Humans; Indoles; Irinotecan; Male; Neoplasms; Pyridines; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1994 |
Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Camptothecin; DNA; DNA Topoisomerases, Type I; Drug Administration Schedule; Female; Humans; Irinotecan; Leukemia; Male; Middle Aged; Topoisomerase I Inhibitors; Topotecan | 1993 |
Phase I clinical trial of weekly combined topotecan and irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Enzyme Inhibitors; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2001 |
Combined topoisomerase I inhibition for the treatment of metastatic colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Maximum Tolerated Dose; Nausea; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Patient Selection; Remission Induction; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Vomiting | 2004 |
Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Humans; Irinotecan; Neoplasms; Topotecan; Treatment Outcome | 2006 |
Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Salvage Therapy; Survival Analysis; Topotecan | 2008 |
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 2014 |
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2016 |
Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cost-Benefit Analysis; Etoposide; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Prognosis; Quality-Adjusted Life Years; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2018 |
143 other study(ies) available for topotecan and irinotecan
Article | Year |
---|---|
Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cattle; Cell Line; Colonic Neoplasms; DNA, Superhelical; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Humans; Indicators and Reagents; Leukemia L1210; Lung Neoplasms; Melanoma, Experimental; Mice; Molecular Structure; Plasmids; Structure-Activity Relationship; Thymus Gland; Topoisomerase I Inhibitors; Transplantation, Heterologous | 1991 |
Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
Topics: Acridines; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Survival; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Neoplasm Proteins; Tetrahydroisoquinolines; Tumor Cells, Cultured | 2001 |
Nitro and amino substitution in the D-ring of 5-(2-dimethylaminoethyl)- 2,3-methylenedioxy-5H-dibenzo[c,h][1,6]naphthyridin-6-ones: effect on topoisomerase-I targeting activity and cytotoxicity.
Topics: Amines; Antineoplastic Agents; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Naphthyridines; Nitro Compounds; Structure-Activity Relationship; Tumor Cells, Cultured | 2003 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Synthesis and topoisomerase poisoning activity of A-ring and E-ring substituted luotonin A derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Humans; Magnetic Resonance Spectroscopy; Pyrroles; Quinones; Spectrometry, Mass, Electrospray Ionization; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2007 |
New homocamptothecins: synthesis, antitumor activity, and molecular modeling.
Topics: Antineoplastic Agents; Binding Sites; Camptothecin; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type I; Humans; Imaging, Three-Dimensional; Imines; Methylation; Models, Molecular; Molecular Structure; Protein Binding; Pyridines; Quantitative Structure-Activity Relationship; Solubility; Water | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
11-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridine derivatives as novel topoisomerase I-targeting agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Leukemia, Lymphoid; Phenanthridines; Structure-Activity Relationship; Topoisomerase I Inhibitors | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Synthesis and antiproliferative evaluation of 6-arylindeno[1,2-c]quinoline derivatives.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; DNA Fragmentation; Drug Screening Assays, Antitumor; G2 Phase; Humans; Indenes; Poly(ADP-ribose) Polymerases; Quinolines; Tubulin | 2009 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Phosphate ester derivatives of homocamptothecin: synthesis, solution stabilities and antitumor activities.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Drug Stability; Esters; Humans; Hydrogen-Ion Concentration; Inhibitory Concentration 50; Molecular Structure; Pharmaceutical Solutions; Phosphates; Structure-Activity Relationship | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatment.
Topics: Administration, Oral; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bone Marrow Cells; Brain; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Male; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasm Transplantation; Species Specificity; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous | 2011 |
Synthesis and antiproliferative evaluation of 6-aryl-11-iminoindeno[1,2-c]quinoline derivatives.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; G1 Phase; Humans; Neoplasms; Quinolines | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations.
Topics: Antineoplastic Agents, Phytogenic; Biological Products; Cell Line, Tumor; Drug Screening Assays, Antitumor; Evodia; Humans; Quinazolines; Structure-Activity Relationship | 2012 |
Camptothecins in tumor homing via an RGD sequence mimetic.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; Integrins; Male; Oligopeptides; Ovarian Neoplasms; Prostatic Neoplasms; Rats | 2012 |
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs | 2013 |
Scaffold Diversity Inspired by the Natural Product Evodiamine: Discovery of Highly Potent and Multitargeting Antitumor Agents.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biological Products; Cell Cycle; Cell Line, Tumor; Drug Design; Drug Discovery; Drug Screening Assays, Antitumor; Evodia; Humans; Models, Molecular; Quinazolines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tubulin Modulators | 2015 |
Synthesis and antitumor activity of novel substituted uracil-1'(N)-acetic acid ester derivatives of 20(S)-camptothecins.
Topics: Acetates; Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type I; Humans; Mice, Nude; Neoplasms; Topoisomerase I Inhibitors; Uracil | 2017 |
Design, synthesis and potent cytotoxic activity of novel 7-(N-[(substituted-sulfonyl)piperazinyl]-methyl)-camptothecin derivatives.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Design; Drug Screening Assays, Antitumor; Humans; Methylation; Neoplasms; Piperazine; Piperazines; Sulfones | 2017 |
Design, synthesis, and cytotoxic activity of novel 7-substituted camptothecin derivatives incorporating piperazinyl-sulfonylamidine moieties.
Topics: Amidines; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Piperazine; Piperazines; Structure-Activity Relationship | 2017 |
Design, semisynthesis and potent cytotoxic activity of novel 10-fluorocamptothecin derivatives.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorine; Humans; Structure-Activity Relationship; Topotecan | 2017 |
Design, synthesis and antineoplastic activity of novel 20(S)-acylthiourea derivatives of camptothecin.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Structure-Activity Relationship; Tumor Cells, Cultured; Urea | 2020 |
Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Humans; Irinotecan; Lung Neoplasms; Small Cell Lung Carcinoma | 2022 |
Reduced albumin binding promotes the stability and activity of topotecan in human blood.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; DNA, Neoplasm; Drug Stability; Electrophoresis, Agar Gel; Flow Cytometry; Fluorescence Polarization; HL-60 Cells; Humans; Irinotecan; Lactones; Molecular Structure; Serum Albumin; Topoisomerase I Inhibitors; Topotecan | 1995 |
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Colonic Neoplasms; Female; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasms, Experimental; Random Allocation; Rhabdomyosarcoma; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1995 |
Topoisomerase I inhibition: a new target or new missiles?
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Drug Design; Drug Synergism; Humans; Irinotecan; Neoplasm Proteins; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1995 |
In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Survival; CHO Cells; Cricetinae; DNA Damage; Drug Resistance; Female; Irinotecan; Leukemia P388; Mice; Topotecan | 1993 |
The structural basis of camptothecin interactions with human serum albumin: impact on drug stability.
Topics: Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Half-Life; Irinotecan; Kinetics; Lactones; Molecular Structure; Serum Albumin; Spectrometry, Fluorescence; Structure-Activity Relationship; Topotecan | 1994 |
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Male; Melphalan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Rhabdomyosarcoma; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Vincristine | 1993 |
Schedule-dependent efficacy of camptothecins in models of human cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Neoplasms, Experimental; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1996 |
Treatment of central nervous system xenografts with camptothecins.
Topics: Adult; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Child; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Topotecan; Transplantation, Heterologous | 1996 |
[New drugs. Topoisomerase inhibitors].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Female; Genital Neoplasms, Female; Humans; Irinotecan; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 1996 |
Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs.
Topics: Acetonitriles; Antineoplastic Agents, Phytogenic; Buffers; Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Ethylamines; Humans; Hydrogen-Ion Concentration; Irinotecan; Lactones; Osmolar Concentration; Topotecan | 1997 |
DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Stability; Enzyme Inhibitors; Flow Cytometry; Humans; Irinotecan; Lung Neoplasms; Solubility; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Water | 1997 |
Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; DNA Fragmentation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Irinotecan; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasm Proteins; Neoplasm Transplantation; Pancreatic Neoplasms; Prodrugs; Splenic Neoplasms; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1997 |
Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1997 |
[Derivatives of camptothecin. A new class of antineoplastic agents].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Ovarian Neoplasms; Topotecan | 1997 |
Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; DNA Adducts; Drug Administration Schedule; Drug Synergism; Humans; In Vitro Techniques; Irinotecan; Topotecan; Tumor Cells, Cultured | 1998 |
DNA-topoisomerase I, a new target for the treatment of neuroblastoma.
Topics: Adrenal Glands; Animals; Antineoplastic Agents; Camptothecin; Child; Child, Preschool; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Female; Ganglioneuroblastoma; Humans; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Proteins; Neuroblastoma; Remission Induction; Topotecan; Transplantation, Heterologous | 1997 |
Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Line; Cross Reactions; Drug Resistance; Enzyme Inhibitors; Female; Glucose; Humans; Irinotecan; Kinetics; Ovarian Neoplasms; Temperature; Topoisomerase I Inhibitors; Topotecan | 1998 |
Colon cancer: new drug options improve on 5-FU.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Folic Acid Antagonists; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Tegafur; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 1998 |
Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Flow Cytometry; Genes, p53; Humans; Irinotecan; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 1998 |
Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cornea; Disease Models, Animal; Fibroblast Growth Factor 2; Irinotecan; Mice; Mice, Inbred Strains; Neovascularization, Pathologic; Neovascularization, Physiologic; Topotecan; Vincristine | 1999 |
Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biopsy; Camptothecin; Caspases; Cell Division; Colonic Neoplasms; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Poly(ADP-ribose) Polymerases; Time Factors; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Drug Resistance, Multiple; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Kinetics; Mitoxantrone; Neoplasm Proteins; Ovarian Neoplasms; Topotecan; Tumor Cells, Cultured | 1999 |
Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1999 |
Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Dose-Response Relationship, Drug; Humans; Irinotecan; Neoplastic Stem Cells; Topotecan; Tumor Cells, Cultured | 1999 |
Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Cell Survival; Genes, p53; Glioma; Humans; Irinotecan; Mice; Mice, Nude; Mutation; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Cell Survival; DNA Damage; Drug Resistance, Multiple; Epirubicin; Female; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Microscopy, Confocal; Mitoxantrone; Polymerase Chain Reaction; Topotecan; Tumor Cells, Cultured | 1999 |
Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines.
Topics: Antineoplastic Agents; Camptothecin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Neuroblastoma; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 2000 |
Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
Topics: Antineoplastic Agents; Biopsy; Camptothecin; Cell Division; Colon; Colonic Neoplasms; Culture Techniques; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Thymidine; Topoisomerase I Inhibitors; Topotecan; Tritium; Tumor Cells, Cultured | 2000 |
Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Enzyme Inhibitors; Humans; Irinotecan; Phosphorylation; Thymidine Kinase; Thymidylate Synthase; Time Factors; Topotecan; Tumor Cells, Cultured; Zidovudine | 2000 |
Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines.
Topics: Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fluorometry; Humans; Irinotecan; Neoplasms; Topotecan; Tumor Cells, Cultured | 2000 |
Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mitoxantrone; Neoplasm Proteins; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 2000 |
The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Cycle; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Humans; Irinotecan; Morpholines; Neoplasm Proteins; Neoplastic Stem Cells; Phosphorylation; Protein-Tyrosine Kinases; Recombinant Fusion Proteins; Topoisomerase I Inhibitors; Topotecan; Transfection; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2001 |
PML and a tale of two drug companies.
Topics: AIDS-Related Opportunistic Infections; Albendazole; Blood-Brain Barrier; Camptothecin; Drug Industry; Humans; Irinotecan; JC Virus; Leukoencephalopathy, Progressive Multifocal; Microsporidiosis; Polymerase Chain Reaction; Topotecan | 1995 |
Making inroads on PML.
Topics: Acquired Immunodeficiency Syndrome; Camptothecin; HIV Protease Inhibitors; Humans; Irinotecan; Leukoencephalopathy, Progressive Multifocal; Topotecan | 1996 |
Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Genes, MDR; Genetic Vectors; HeLa Cells; Humans; Irinotecan; Mitoxantrone; Mutation; Neoplasm Proteins; Rhodamine 123; RNA, Messenger; Substrate Specificity; Topotecan; Transfection; Tumor Cells, Cultured; Vaccinia virus | 2001 |
Comparison of camptothecin derivatives presently in clinical trials: genotoxic potency and mitotic recombination.
Topics: Animals; Camptothecin; Clinical Trials as Topic; DNA Damage; Drosophila melanogaster; Enzyme Inhibitors; Female; Irinotecan; Male; Mutagenicity Tests; Mutation; Recombination, Genetic; Topoisomerase I Inhibitors; Topotecan; Wings, Animal | 2002 |
Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrone; Female; Flow Cytometry; Humans; Irinotecan; K562 Cells; Mitoxantrone; Neoplasm Proteins; Topoisomerase I Inhibitors; Topotecan; Transfection | 2002 |
Clinical trials using irinotecan.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Chromosome Breakage; Clinical Trials as Topic; DNA Damage; DNA Replication; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Administration Schedule; Enzyme Inhibitors; Humans; Irinotecan; Mice; Multicenter Studies as Topic; Neoplasm Proteins; Neuroblastoma; Rhabdomyosarcoma; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2002 |
Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Division; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasm Transplantation; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 2002 |
Unexpected pleural effusions in 3 pediatric patients treated with STI-571.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Camptothecin; Child; Combined Modality Therapy; Edema; Enzyme Inhibitors; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Lung Neoplasms; Male; Neoplasm Proteins; Neuroectodermal Tumors, Primitive; Piperazines; Pleural Effusion; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Sarcoma, Ewing; Testis; Topotecan | 2002 |
C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.
Topics: Alternative Splicing; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Base Sequence; Blotting, Northern; Blotting, Western; Camptothecin; DNA, Complementary; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fibroblasts; Heterozygote; Homozygote; Irinotecan; Mice; Mitoxantrone; Molecular Sequence Data; Mutation; Neoplasm Proteins; Polymorphism, Genetic; RNA, Messenger; Sequence Analysis, DNA; Topotecan; Transfection; Tumor Cells, Cultured | 2002 |
[A symphony for the camptothecins].
Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Irinotecan; Music; Neoplasms; Organosilicon Compounds; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan | 2003 |
Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Division; Cell Line; Cisplatin; Deoxycytidine; DNA, Neoplasm; Docetaxel; Drug Screening Assays, Antitumor; Fenretinide; Flow Cytometry; Gemcitabine; Humans; Irinotecan; Mesothelioma; Paclitaxel; Taxoids; Topotecan | 2003 |
Expression and functional analyses of breast cancer resistance protein in lung cancer.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Transport; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topotecan | 2003 |
Apoptotic pathways of epothilone BMS 310705.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Caspases; Cytochrome c Group; Drug Resistance, Neoplasm; Enzyme Activation; Epothilones; Female; Humans; Irinotecan; Isoenzymes; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Topotecan; Tumor Cells, Cultured | 2003 |
Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; In Vitro Techniques; Irinotecan; Lethal Dose 50; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Topotecan; Tumor Cells, Cultured | 2003 |
Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Topics: Aminocoumarins; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Coumarins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Novobiocin; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 2004 |
Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma.
Topics: Adolescent; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Infant; Irinotecan; Male; Mesna; Neuroblastoma; Retrospective Studies; Topotecan | 2004 |
Pheophorbide a is a specific probe for ABCG2 function and inhibition.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Chlorophyll; Drug Resistance, Neoplasm; Humans; Irinotecan; Neoplasm Proteins; Quinolines; Staurosporine; Topotecan | 2004 |
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Bone Neoplasms; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Irinotecan; Neoplasm Proteins; Osteosarcoma; Piperazines; Pyrimidines; Topotecan | 2004 |
[Structure-activity relationship analysis].
Topics: Antineoplastic Agents; Benzamides; Camptothecin; Docetaxel; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Imatinib Mesylate; Irinotecan; Macrolides; Oligopeptides; Paclitaxel; Piperazines; Pyrimidines; Quinazolines; Structure-Activity Relationship; Taxoids; Topotecan; Vinblastine | 2004 |
Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Baculoviridae; Benzimidazoles; Biological Transport; Camptothecin; Cell Line; DNA, Complementary; Dogs; Drug Interactions; Enzyme Inhibitors; Humans; Irinotecan; Membrane Transport Proteins; Methotrexate; Mice; Mice, Knockout; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Omeprazole; Pantoprazole; Spodoptera; Sulfoxides; Topotecan; Transfection | 2004 |
Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Estrone; Gefitinib; Humans; Irinotecan; Neoplasm Proteins; Quinazolines; Topotecan | 2004 |
HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand.
Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Drug Synergism; Endoribonucleases; Enzyme Inhibitors; Humans; Irinotecan; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase 4; Membrane Glycoproteins; Mitogen-Activated Protein Kinase Kinases; Oligoribonucleotides; Prostatic Neoplasms; TNF-Related Apoptosis-Inducing Ligand; Topoisomerase I Inhibitors; Topotecan; Transfection; Tumor Necrosis Factor-alpha | 2004 |
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Topics: Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Breast Neoplasms; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Topotecan | 2005 |
MEN4901/T-0128, a new camptothecin derivative-carboxymethyldextran conjugate, has potent antitumor activities in a panel of human tumor xenografts in nude mice.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Body Weight; Camptothecin; Cell Line, Tumor; Dextrans; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Time Factors; Topotecan; Treatment Outcome; Xenograft Model Antitumor Assays | 2005 |
Fluorescence detection combined with either HPLC or HPTLC for pharmaceutical quality control in a hospital chemotherapy production unit: application to camptothecin derivatives.
Topics: Antineoplastic Agents; Calibration; Camptothecin; Chemistry, Pharmaceutical; Chromatography; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Densitometry; Drug Industry; Drug Stability; Irinotecan; Models, Chemical; Pharmaceutical Preparations; Quality Control; Reproducibility of Results; Spectrometry, Fluorescence; Technology, Pharmaceutical; Topotecan | 2005 |
Cancer cell adaptation to chemotherapy.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biopsy; Camptothecin; Cell Line, Tumor; Cisplatin; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Drug Therapy; Epirubicin; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Neoplasms; Paclitaxel; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Topotecan; Treatment Outcome; Up-Regulation | 2005 |
The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan.
Topics: Antineoplastic Agents; Camptothecin; Caspase 3; Caspases; Cell Cycle; Cell Line, Tumor; Comet Assay; Humans; In Situ Nick-End Labeling; In Vitro Techniques; Irinotecan; Neuroblastoma; Topotecan | 2005 |
Esters and amides of 2,3-dimethoxy-8,9-methylenedioxy-benzo[i]phenanthridine-12-carboxylic acid: potent cytotoxic and topoisomerase I-targeting agents.
Topics: Amides; Camptothecin; Cell Line; Cell Survival; DNA; DNA Topoisomerases, Type I; Enzyme Inhibitors; Esters; Humans; Inhibitory Concentration 50; Irinotecan; Molecular Structure; Topoisomerase I Inhibitors; Topotecan | 2005 |
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
Topics: Adenosine Triphosphatases; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Humans; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spectrometry, Fluorescence; Topoisomerase I Inhibitors; Topotecan | 2006 |
Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Camptothecin; Enzyme Inhibitors; Female; HT29 Cells; Humans; Indoles; Irinotecan; Mice; Neoplasm Proteins; Neoplasms, Experimental; Staining and Labeling; Topotecan; Vacuolar Proton-Translocating ATPases | 2006 |
[Is small cell lung cancer an orphan disease?].
Topics: Administration, Oral; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Prevalence; Randomized Controlled Trials as Topic; Sex Factors; Thalidomide; Topotecan; Vincristine | 2006 |
[From ASCO and WCLC 2005 to clinical practice: "conventional" treatments].
Topics: Administration, Oral; Age Factors; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung; Lung Neoplasms; Mediastinoscopy; Meta-Analysis as Topic; Middle Aged; Neoplasm Staging; Palliative Care; Pneumonectomy; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Taxoids; Time Factors; Topotecan | 2006 |
Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; DNA Fragmentation; Dose-Response Relationship, Drug; Glucuronidase; Glucuronides; Humans; Hybridomas; Hydrogen-Ion Concentration; Hydrolysis; Immunoconjugates; Inhibitory Concentration 50; Irinotecan; Lactones; Molecular Structure; Prodrugs; Serum Albumin; Thymidine; Time Factors; Topotecan; Tritium | 2007 |
Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo.
Topics: Animals; Apoptosis; Camptothecin; Cell Line, Tumor; DNA Damage; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Female; HL-60 Cells; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Models, Molecular; Topotecan | 2007 |
Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Endpoint Determination; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Patient Compliance; Salvage Therapy; Topotecan | 2008 |
Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Dogs; Drug Resistance, Neoplasm; Gene Expression; Humans; Irinotecan; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Mutation; Topotecan; Transfection | 2008 |
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Mass Index; Body Size; Body Surface Area; Body Weight; Camptothecin; Carboplatin; Cisplatin; Cytosine; Dioxolanes; Docetaxel; Doxorubicin; Humans; Irinotecan; Metabolic Clearance Rate; Obesity; Paclitaxel; Taxoids; Topotecan | 2007 |
Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1 recessive neomorphic mutation?
Topics: Animals; Antineoplastic Agents; Axons; Bleomycin; Brain; Camptothecin; Cells, Cultured; Comet Assay; Embryo, Mammalian; Etoposide; Fibroblasts; Genes, Recessive; Humans; Irinotecan; Mice; Mice, Knockout; Mutation; Phosphoric Diester Hydrolases; Polyneuropathies; RNA, Messenger; Spinocerebellar Ataxias; Topotecan | 2007 |
Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis.
Topics: Administration, Oral; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cost-Benefit Analysis; Cyclophosphamide; Doxorubicin; Etoposide; Female; Health Care Costs; Humans; Infusions, Intravenous; Insurance Claim Review; Irinotecan; Male; Middle Aged; Retrospective Studies; Topotecan; United States; Vincristine | 2008 |
Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cytarabine; Deoxycytidine; Drug Interactions; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Hydrazines; Idarubicin; Irinotecan; Leukemia; Lymphoma; Sulfonamides; Topotecan | 2008 |
Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors.
Topics: Animals; Antineoplastic Agents; Body Weight; Bone Marrow; Camptothecin; Cell Line, Tumor; Cell Proliferation; Confidence Intervals; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Inhibitory Concentration 50; Irinotecan; Male; Mice; Mice, Inbred BALB C; Naphthyridines; Neoplastic Stem Cells; Topoisomerase I Inhibitors; Topotecan; Weight Loss; Xenograft Model Antitumor Assays | 2008 |
Lack of stability of topotecan in heart tissue homogenates: is it an analytical dilemma or a real phenomenon?
Topics: Animals; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Humans; Irinotecan; Mice; Myocardium; Tandem Mass Spectrometry; Topotecan | 2009 |
Molecular cytogenetic evaluation of the mechanism of micronuclei formation induced by camptothecin, topotecan, and irinotecan.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Camptothecin; Cytogenetics; DNA Probes; DNA, Satellite; In Situ Hybridization, Fluorescence; Injections, Intraperitoneal; Irinotecan; Male; Mice; Micronuclei, Chromosome-Defective; Micronucleus Tests; Topotecan | 2009 |
NDRG1 is down-regulated in the early apoptotic event induced by camptothecin analogs: the potential role in proteolytic activation of PKC delta and apoptosis.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle Proteins; Down-Regulation; Doxorubicin; Enzyme Activation; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Protein Kinase C-delta; RNA, Small Interfering; Topotecan; Transcription, Genetic; U937 Cells | 2009 |
7-Cycloalkylcamptothecin derivatives: Preparation and biological evaluation.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Chemistry, Pharmaceutical; Colorectal Neoplasms; Drug Design; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; Hydrolysis; Inhibitory Concentration 50; Irinotecan; Models, Chemical; Rhodamines; Structure-Activity Relationship; Topotecan | 2009 |
Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carbazoles; Cyclophosphamide; Dacarbazine; Enzyme Activation; Furans; Humans; Irinotecan; Mice; Mice, Nude; Neuroblastoma; Receptor, trkB; Temozolomide; Topotecan; Xenograft Model Antitumor Assays | 2010 |
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cyclophosphamide; Dose-Response Relationship, Drug; Endothelial Cells; Female; Humans; Indazoles; Irinotecan; Mice; Mice, SCID; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Topotecan; Xenograft Model Antitumor Assays | 2010 |
Comparison of DC Bead-irinotecan and DC Bead-topotecan drug eluting beads for use in locoregional drug delivery to treat pancreatic cancer.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Humans; Irinotecan; Pancreatic Neoplasms; Topotecan | 2010 |
[Hematological toxicity of some combined chemotherapy schemes involving aranoza].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Glycosides; Hematologic Tests; Irinotecan; Lymphopenia; Male; Methylnitrosourea; Mice; Mice, Inbred BALB C; Neutropenia; Topotecan | 2010 |
High antimetastatic efficacy of MEN4901/T-0128, a novel camptothecin carboxymethyldextran conjugate.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Colonic Neoplasms; Dextrans; Dose-Response Relationship, Drug; Green Fluorescent Proteins; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Prodrugs; Topotecan; Xenograft Model Antitumor Assays | 2011 |
Laser induced fluorescence and photochemical derivatization for trace determination of camptothecin.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Fluorescence; Irinotecan; Lasers; Pharmaceutical Preparations; Photochemistry; Sensitivity and Specificity; Spectrometry, Fluorescence; Topotecan | 2010 |
High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Cohort Studies; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Infant; Infant, Newborn; Irinotecan; Male; Neuroblastoma; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Temozolomide; Topotecan; Treatment Outcome | 2011 |
Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons.
Topics: Camptothecin; Cell Line, Tumor; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Endocytosis; Floxuridine; Fluorodeoxyuridylate; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Irinotecan; MicroRNAs; National Cancer Institute (U.S.); Nucleosides; RNA, Messenger; Topoisomerase I Inhibitors; Topotecan; United States | 2010 |
Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Dactinomycin; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Infratentorial Neoplasms; Irinotecan; Melphalan; Neoplasm Metastasis; Neuroblastoma; Rhabdomyosarcoma; Thiotepa; Topotecan; Vincristine | 2011 |
MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biphenyl Compounds; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colonic Neoplasms; Doxorubicin; Drug Synergism; Female; Genomics; Humans; Irinotecan; Kinetics; Multidrug Resistance-Associated Proteins; Necrosis; Neoplasm Proteins; Signal Transduction; Tetrahydroisoquinolines; Topotecan | 2011 |
Neurodevelopmental disorders. New hope for a devastating neurological disorder.
Topics: Angelman Syndrome; Animals; Brain; Camptothecin; Drug Evaluation, Preclinical; Gene Expression Regulation; Genetic Therapy; Humans; Irinotecan; Mice; Neurons; Topotecan; Transcriptional Activation; Ubiquitin-Protein Ligases | 2011 |
Development of a combination drug-eluting bead: towards enhanced efficacy for locoregional tumour therapies.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Doxorubicin; Humans; Irinotecan; Liver Neoplasms; Mice; Mice, Nude; Pancreatic Neoplasms; Prostheses and Implants; Sirolimus; Topotecan; Xenograft Model Antitumor Assays | 2012 |
The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
Topics: Androstadienes; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Morpholines; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Topotecan; Wortmannin | 2012 |
EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.
Topics: Adenosine; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; BRCA1 Protein; Camptothecin; Diketopiperazines; DNA Topoisomerases, Type I; Female; Gene Expression; Heterocyclic Compounds, 4 or More Rings; Irinotecan; Mammary Glands, Animal; Mammary Neoplasms, Animal; Mice; Mice, Knockout; Mutation; Polyethylene Glycols; Survival Rate; Topoisomerase I Inhibitors; Topotecan | 2012 |
Common variants of Drosophila melanogaster Cyp6d2 cause camptothecin sensitivity and synergize with loss of Brca2.
Topics: Animals; BRCA2 Protein; Camptothecin; Cytochrome P-450 Enzyme System; DNA Damage; DNA Primers; DNA Repair; Drosophila melanogaster; Drosophila Proteins; Drug Evaluation, Preclinical; Genetic Complementation Test; Insect Proteins; Irinotecan; Polymorphism, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Topoisomerase I Inhibitors; Topotecan | 2013 |
Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Cohort Studies; Etoposide; Female; Humans; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma; Time Factors; Topotecan; Treatment Outcome | 2015 |
Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Topotecan | 2013 |
Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
Topics: Acridines; Administration, Intravenous; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Camptothecin; Chromatography, High Pressure Liquid; Irinotecan; Mice; Mice, Knockout; Multidrug Resistance-Associated Proteins; Tetrahydroisoquinolines; Topotecan | 2013 |
Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Genital Neoplasms, Female; Humans; Irinotecan; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Exenteration; Prognosis; Retrospective Studies; Survival Rate; Topotecan | 2013 |
Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Folic Acid; HeLa Cells; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Nude; Neoplasms; Neoplasms, Experimental; Paclitaxel; Taxoids; Topotecan; Treatment Outcome; Vinca Alkaloids; Xenograft Model Antitumor Assays | 2014 |
Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Synergism; Enzyme Inhibitors; Humans; Irinotecan; Small Cell Lung Carcinoma; Topotecan | 2014 |
Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.
Topics: Administration, Metronomic; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Inhibitory Concentration 50; Irinotecan; Mice, SCID; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Topotecan; Treatment Outcome | 2014 |
Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Cisplatin; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Sirolimus; Tetrahydroisoquinolines; Topotecan; Trabectedin; Tumor Cells, Cultured | 2014 |
ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
Topics: Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; DNA Replication; DNA Topoisomerases, Type I; Histones; HT29 Cells; Humans; Irinotecan; Organothiophosphorus Compounds; Phosphorylation; Protein Kinases; Pyrazines; Replication Origin; Single-Cell Analysis; Sulfones; Topoisomerase I Inhibitors; Topotecan | 2014 |
[DNA topoisomerase I--targeting drugs].
Topics: Camptothecin; Humans; Irinotecan; Molecular Targeted Therapy; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2015 |
Topoisomerase-I PS506 as a Dual Function Cancer Biomarker.
Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colonic Neoplasms; DNA Topoisomerases, Type I; Female; Gene Expression; Humans; Irinotecan; Lung; Lung Neoplasms; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Phosphorylation; Serine; Topotecan | 2015 |
Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Female; Glucuronidase; Glucuronides; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Prodrugs; Topotecan | 2016 |
5-Flurouracil disrupts nuclear export and nuclear pore permeability in a calcium dependent manner.
Topics: Active Transport, Cell Nucleus; Antimetabolites, Antineoplastic; Apoptosis; Calcium; Camptothecin; Caspases; Cell Nucleus; DNA Topoisomerases, Type I; Drug Interactions; Egtazic Acid; Fluorouracil; HeLa Cells; Humans; Irinotecan; Neoplasm Proteins; Nuclear Pore; Permeability; ran GTP-Binding Protein; Topotecan; Tumor Suppressor Protein p53 | 2017 |
Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; DNA Topoisomerases, Type I; Female; Humans; Irinotecan; Liposomes; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Random Allocation; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2017 |
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy.
Topics: Animals; Cell Line, Tumor; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Immunotherapy, Adoptive; Irinotecan; Lymphocytes, Tumor-Infiltrating; Melanoma; Mice; Mice, Inbred C57BL; T-Lymphocytes, Cytotoxic; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Selective binding and controlled release of anticancer drugs by polyanionic cyclodextrins.
Topics: Acetates; Antineoplastic Agents; Cyclodextrins; Delayed-Action Preparations; Doxorubicin; Drug Carriers; Drug Liberation; Hydrogen-Ion Concentration; Irinotecan; Propionates; Topotecan | 2018 |
Neuroblastoma Cell Lines Are Refractory to Genotoxic Drug-Mediated Induction of Ligands for NK Cell-Activating Receptors.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cisplatin; Cytotoxicity, Immunologic; DNA Damage; Etoposide; Humans; Immunotherapy, Adoptive; Irinotecan; Killer Cells, Natural; Neuroblastoma; Reactive Oxygen Species; Topotecan; Tumor Suppressor Protein p53 | 2018 |
Pro-guest and acyclic cucurbit[n]uril conjugated polymers for the controlled release of anti-tumor drugs.
Topics: Antineoplastic Agents; Berberine; Bridged-Ring Compounds; Camptothecin; Doxorubicin; Drug Carriers; Drug Liberation; Fluorescent Dyes; HeLa Cells; Humans; Hydrogen-Ion Concentration; Imidazoles; Irinotecan; Mitoxantrone; Polymers; Topotecan | 2018 |
The clinical conundrum of managing relapsed small cell lung cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Carboplatin; Clinical Decision-Making; Disease Progression; Etoposide; Humans; Immunoconjugates; Irinotecan; Liver Neoplasms; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Piperazines; Pyrimidines; Salvage Therapy; Small Cell Lung Carcinoma; Temozolomide; Thiourea; Topotecan | 2019 |
Safety and Tolerability of Topotecan-Eluting Radiopaque Microspheres for Hepatic Chemoembolization in a Rabbit Preclinical Model.
Topics: Animals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Irinotecan; Liver Neoplasms; Liver Neoplasms, Experimental; Microspheres; Rabbits; Topoisomerase I Inhibitors; Topotecan | 2020 |
Evaluation of a safe infusion device on reducing occupational exposure of nurses to antineoplastic drugs: a comparative prospective study. Contamoins-1.
Topics: Antineoplastic Agents; Cyclophosphamide; Gloves, Protective; Humans; Infusions, Intravenous; Irinotecan; Nurses; Occupational Exposure; Pemetrexed; Topotecan | 2021 |
Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Proliferation; Deoxycytidine; DNA Replication; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Isoxazoles; Lung Neoplasms; Mice; Mice, Nude; Morpholines; Pyrazines; Pyrazoles; Small Cell Lung Carcinoma; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Comparative Outcomes of Second-line Topoisomerase-I Inhibitor Therapies on Neuroendocrine Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Female; Humans; Irinotecan; Male; Retrospective Studies; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2023 |
Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels.
Topics: Antineoplastic Agents; Busulfan; Carboplatin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Fluorouracil; Ganciclovir; Humans; Idarubicin; Ifosfamide; Irinotecan; Methanol; Methotrexate; Oxaliplatin; Paclitaxel; Pemetrexed; Tandem Mass Spectrometry; Topotecan; Vinblastine; Vincristine; Water | 2022 |
Drug-Induced Conformational Dynamics of P-Glycoprotein Underlies the Transport of Camptothecin Analogs.
Topics: Adenosine Triphosphate; Adenylyl Imidodiphosphate; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Irinotecan; Protein Conformation; Topotecan | 2023 |